Review



pher2 y1196  (Danaher Inc)


Bioz Verified Symbol Danaher Inc is a verified supplier
Bioz Manufacturer Symbol Danaher Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Danaher Inc pher2 y1196
    Pher2 Y1196, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2 y1196/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 y1196 - by Bioz Stars, 2025-01
    86/100 stars

    Images



    Similar Products

    pher2 y1196  (Danaher Inc)
    86
    Danaher Inc pher2 y1196
    Pher2 Y1196, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2 y1196/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 y1196 - by Bioz Stars, 2025-01
    86/100 stars
    		  Buy from Supplier
    pher2 y1196 d66b7  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc pher2 y1196 d66b7
    A Western blots demonstrating increase in <t>pHER2</t> and downstream signaling in sh MLH1 MCF7 cells treated with fulvestrant relative to sh Luc cells. Quantification of four independent replicates conducted through ImageJ in accompanying dot plots. Validation in T47D cells in Fig. . Immunofluorescent staining for HER2 in MCF7 sh Luc and sh MLH1 cells in vitro ( B ), in MCF7 sh Luc and sh MLH1 xenograft tumors ( C ), and in WHIM20, PMS2 mutant, ER + /HER2 − PDX tumors ( D ), grown with or without fulvestrant. Accompanying quantification presented as strip charts. Three independent experiments or tumors from each group were quantified. Two-sided Student’s t test determined p values. Supporting data from FACS analysis are presented in Fig. . Scale bars represent 50 µ. Source data for all figures available with paper.
    Pher2 Y1196 D66b7, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pher2 y1196 d66b7/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pher2 y1196 d66b7 - by Bioz Stars, 2025-01
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    A Western blots demonstrating increase in pHER2 and downstream signaling in sh MLH1 MCF7 cells treated with fulvestrant relative to sh Luc cells. Quantification of four independent replicates conducted through ImageJ in accompanying dot plots. Validation in T47D cells in Fig. . Immunofluorescent staining for HER2 in MCF7 sh Luc and sh MLH1 cells in vitro ( B ), in MCF7 sh Luc and sh MLH1 xenograft tumors ( C ), and in WHIM20, PMS2 mutant, ER + /HER2 − PDX tumors ( D ), grown with or without fulvestrant. Accompanying quantification presented as strip charts. Three independent experiments or tumors from each group were quantified. Two-sided Student’s t test determined p values. Supporting data from FACS analysis are presented in Fig. . Scale bars represent 50 µ. Source data for all figures available with paper.

    Journal: Nature Communications

    Article Title: Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

    doi: 10.1038/s41467-021-23271-0

    Figure Lengend Snippet: A Western blots demonstrating increase in pHER2 and downstream signaling in sh MLH1 MCF7 cells treated with fulvestrant relative to sh Luc cells. Quantification of four independent replicates conducted through ImageJ in accompanying dot plots. Validation in T47D cells in Fig. . Immunofluorescent staining for HER2 in MCF7 sh Luc and sh MLH1 cells in vitro ( B ), in MCF7 sh Luc and sh MLH1 xenograft tumors ( C ), and in WHIM20, PMS2 mutant, ER + /HER2 − PDX tumors ( D ), grown with or without fulvestrant. Accompanying quantification presented as strip charts. Three independent experiments or tumors from each group were quantified. Two-sided Student’s t test determined p values. Supporting data from FACS analysis are presented in Fig. . Scale bars represent 50 µ. Source data for all figures available with paper.

    Article Snippet: Antibodies used were pHER2 Y1196 (D66B7) (Cell Signaling; cat# 6942S), total HER2 (Thermo Scientific; NeoMarkers; cat# MS-730-P1ABX), pAkt S473 (D9E) XP (Cell Signaling; cat#4060S), total Akt (Cell Signaling; cat#9272S), pS6 (S235/236) (Cell Signaling; cat# 2211S), total S6 (5G10) (Cell Signaling; cat# 2217S), MLH1 (1:2,000, Sigma-Aldrich; cat# WH0004292M2), ER clone 60C (EMD Millipore; cat# 04-820), and GAPDH (0411) (Santa Cruz; cat# sc-47724).

    Techniques: Western Blot, Staining, In Vitro, Mutagenesis, Stripping Membranes